Chicago Equity Partners LLC cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,200 shares of the biopharmaceutical company’s stock after selling 9,905 shares during the quarter. Chicago Equity Partners LLC’s holdings in Halozyme Therapeutics were worth $1,148,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC grew its holdings in Halozyme Therapeutics by 69.1% in the second quarter. Cubist Systematic Strategies LLC now owns 22,346 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 9,134 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd acquired a new stake in Halozyme Therapeutics in the third quarter worth $21,690,000. Rhumbline Advisers grew its holdings in Halozyme Therapeutics by 7.0% in the second quarter. Rhumbline Advisers now owns 132,784 shares of the biopharmaceutical company’s stock worth $2,240,000 after purchasing an additional 8,703 shares during the period. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 76.0% in the second quarter. Dimensional Fund Advisors LP now owns 643,822 shares of the biopharmaceutical company’s stock worth $10,862,000 after purchasing an additional 277,953 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Halozyme Therapeutics by 60.3% in the second quarter. Wells Fargo & Company MN now owns 535,697 shares of the biopharmaceutical company’s stock worth $9,038,000 after purchasing an additional 201,507 shares during the period. Institutional investors own 84.68% of the company’s stock.

Halozyme Therapeutics stock opened at $15.32 on Thursday. Halozyme Therapeutics, Inc. has a 1-year low of $14.33 and a 1-year high of $21.48. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of 34.04 and a beta of 1.88. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.96 and a current ratio of 3.09.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. The firm had revenue of $25.60 million for the quarter, compared to analyst estimates of $30.42 million. During the same period last year, the firm earned $0.02 earnings per share. The business’s quarterly revenue was down 59.8% compared to the same quarter last year. Equities research analysts predict that Halozyme Therapeutics, Inc. will post -0.59 EPS for the current year.

In related news, major shareholder Randal J. Kirk sold 1,194,462 shares of the firm’s stock in a transaction dated Thursday, August 23rd. The shares were sold at an average price of $17.65, for a total transaction of $21,082,254.30. Following the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at $62,876,148.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Randal J. Kirk sold 161,246 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $17.15, for a total transaction of $2,765,368.90. Following the transaction, the insider now directly owns 3,562,388 shares in the company, valued at $61,094,954.20. The disclosure for this sale can be found here. Insiders sold 2,000,706 shares of company stock worth $35,509,187 over the last ninety days. Insiders own 14.10% of the company’s stock.

HALO has been the subject of a number of research reports. ValuEngine cut shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 8th. Piper Jaffray Companies restated a “neutral” rating on shares of Halozyme Therapeutics in a report on Friday, October 19th. Cantor Fitzgerald initiated coverage on shares of Halozyme Therapeutics in a report on Wednesday, August 22nd. They issued an “overweight” rating and a $27.00 price target for the company. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Finally, Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.56.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/11/15/halozyme-therapeutics-inc-halo-stake-decreased-by-chicago-equity-partners-llc.html.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Story: Retained Earnings

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.